- Home
- CMP vs URGN Comparison
CMP vs URGN Comparison
Compare CMP & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMP
- URGN
- Stock Information
- Founded
- CMP 1993
- URGN 2004
- Country
- CMP United States
- URGN United States
- Employees
- CMP N/A
- URGN N/A
- Industry
- CMP Other Metals and Minerals
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- CMP Basic Materials
- URGN Health Care
- Exchange
- CMP Nasdaq
- URGN Nasdaq
- Market Cap
- CMP 781.2M
- URGN 904.0M
- IPO Year
- CMP 2003
- URGN 2017
- Fundamental
- Price
- CMP $17.95
- URGN $18.72
- Analyst Decision
- CMP Hold
- URGN Strong Buy
- Analyst Count
- CMP 3
- URGN 8
- Target Price
- CMP $20.00
- URGN $28.50
- AVG Volume (30 Days)
- CMP 325.1K
- URGN 1.2M
- Earning Date
- CMP 08-11-2025
- URGN 11-05-2025
- Dividend Yield
- CMP N/A
- URGN N/A
- EPS Growth
- CMP N/A
- URGN N/A
- EPS
- CMP N/A
- URGN N/A
- Revenue
- CMP $1,225,200,000.00
- URGN $94,238,000.00
- Revenue This Year
- CMP $12.05
- URGN $39.63
- Revenue Next Year
- CMP $4.15
- URGN $111.49
- P/E Ratio
- CMP N/A
- URGN N/A
- Revenue Growth
- CMP 7.27
- URGN 10.85
- 52 Week Low
- CMP $8.60
- URGN $3.42
- 52 Week High
- CMP $22.69
- URGN $21.71
- Technical
- Relative Strength Index (RSI)
- CMP 37.71
- URGN 49.21
- Support Level
- CMP $17.90
- URGN $17.89
- Resistance Level
- CMP $18.68
- URGN $21.71
- Average True Range (ATR)
- CMP 0.64
- URGN 1.18
- MACD
- CMP -0.04
- URGN -0.25
- Stochastic Oscillator
- CMP 15.59
- URGN 21.73
About CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.